Literature DB >> 24930586

Mortality of patients with bullous pemphigoid in Korea.

Ji Hye Lee1, Soo-Chan Kim2.   

Abstract

BACKGROUND: The reported mortality rates and prognoses of bullous pemphigoid (BP) vary among different countries. However, the mortality rate of BP has not been investigated in Korea.
OBJECTIVE: We sought to evaluate the mortality rate of Korean patients with BP in comparison to that of an age-matched general population in Korea, and to identify prognostic factors affecting overall survival.
METHODS: We conducted a retrospective analysis of 168 patients diagnosed with BP between 1993 and 2013 at Gangnam Severance Hospital in Seoul, Korea.
RESULTS: The 1-, 2-, and 5-year mortality rates of BP patients were 19.46% (95% confidence interval [CI], 13.83-27.00), 29.13% (95% CI, 21.91-38.08), and 58.03% (95% CI, 47.04-69.45), respectively. The median age was 73 years (range, 6-99 years). The standardized mortality ratio ranged from 2.43 (95% CI, 0.12-11.96) to 9.56 (95% CI, 2.43-26.02), depending on the age group. In multivariate analysis, old age at the time of diagnosis, stroke, diabetes, and delayed diagnosis were associated with increased mortality. LIMITATIONS: This study was conducted as a retrospective analysis and was based at a single institution.
CONCLUSION: The mortality rate of patients with BP is significantly higher than that for the general population.
Copyright © 2014 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Korea; autoimmune bullous disease; bullous pemphigoid; mortality; prognosis

Mesh:

Year:  2014        PMID: 24930586     DOI: 10.1016/j.jaad.2014.05.006

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  14 in total

1.  Assessment of the Prevalence of Mucosal Involvement in Bullous Pemphigoid.

Authors:  Khalaf Kridin; Reuven Bergman
Journal:  JAMA Dermatol       Date:  2019-02-01       Impact factor: 10.282

Review 2.  Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and Management.

Authors:  Kyle T Amber; Dedee F Murrell; Enno Schmidt; Pascal Joly; Luca Borradori
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

3.  Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes: Estimating the Risk of the New Agents and Characterizing the Patients.

Authors:  Khalaf Kridin; Reuven Bergman
Journal:  JAMA Dermatol       Date:  2018-10-01       Impact factor: 10.282

4.  Clinical Effectiveness and Safety of Initial Combination Therapy with Corticosteroids and Rituximab in Bullous Pemphigoid: A Retrospective Cohort Study.

Authors:  Yun-Ju Tsai; Yung-Tsu Cho; Chia-Yu Chu
Journal:  Am J Clin Dermatol       Date:  2022-05-17       Impact factor: 6.233

5.  Prognostic factors for mortality in patients with bullous pemphigoid: a meta-analysis.

Authors:  Yi-Di Liu; Yan-Hong Wang; Yi-Cong Ye; Wen-Ling Zhao; Li Li
Journal:  Arch Dermatol Res       Date:  2017-03-19       Impact factor: 3.017

Review 6.  Comorbidities and Treatment Strategies in Bullous Pemphigoid: An Appraisal of the Existing Litterature.

Authors:  Rikke Bech; Line Kibsgaard; Christian Vestergaard
Journal:  Front Med (Lausanne)       Date:  2018-09-04

Review 7.  Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid.

Authors:  Kaisa Tasanen; Outi Varpuluoma; Wataru Nishie
Journal:  Front Immunol       Date:  2019-06-04       Impact factor: 8.786

8.  Mortality and Comorbidity Profiles of Patients with Bullous Pemphigoid in Korea.

Authors:  Hyeon Woo Jeon; Sook Jung Yun; Seung-Chul Lee; Young Ho Won; Jee-Bum Lee
Journal:  Ann Dermatol       Date:  2017-12-26       Impact factor: 1.444

9.  Explosive bullous pemphigoid with high serum total IgE: Serum IgE as a biomarker that reflects disease activity.

Authors:  Hyun Jung Kwon; Ga Ram Ahn; Sun Young Choi; Kapsok Li; Seong Jun Seo
Journal:  JAAD Case Rep       Date:  2018-04-04

10.  Assessment of the Characteristics and Associated Factors of Infectious Complications in Bullous Pemphigoid.

Authors:  Jia Chen; Xuming Mao; Wenling Zhao; Bingjie Zhang; Xinyi Chen; Chenyang Yu; Zehui Zheng; Hongzhong Jin; Li Li
Journal:  Front Immunol       Date:  2020-07-23       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.